These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20671879)

  • 1. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
    Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
    Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.
    Castrillo A; Cardoso M; Rouse L
    Transfus Med Hemother; 2013 Feb; 40(1):44-8. PubMed ID: 23637649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS.
    Janetzko K; Hinz K; Marschner S; Goodrich R; Klüter H
    Vox Sang; 2009 Oct; 97(3):234-9. PubMed ID: 19790298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
    Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
    Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of use of riboflavin and ultraviolet light for pathogen inactivation on quality of platelet concentrates].
    Stanojković Z; Antić A; Stojanović M
    Vojnosanit Pregl; 2011 Jun; 68(6):489-94. PubMed ID: 21818915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
    Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
    Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
    Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
    Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.
    van der Meer PF; Couture C; Hervig T; Kruit G; Devine DV; de Korte D; Kerkhoffs JL
    Vox Sang; 2017 Jan; 112(1):9-17. PubMed ID: 28001293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
    Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
    Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality assessment of buffy-coat-derived leucodepleted platelet concentrates in PAS-plasma, prepared by the OrbiSac or TACSI automated system.
    Plaza EM; Céspedes P; Fernández H; Sánchez-Guiu MI; Egea JM; Vicente V; Lozano ML; Rivera J
    Vox Sang; 2014 Jan; 106(1):38-44. PubMed ID: 23888911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
    Reid S; Johnson L; Woodland N; Marks DC
    Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
    Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
    Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: maintained in vitro quality over 7-day storage.
    Ohlsson S; Diedrich B; Uhlin M; Sandgren P
    Vox Sang; 2018 Oct; 113(7):611-621. PubMed ID: 30156292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.
    Plaza EM; Lozano ML; Guiu IS; Egea JM; Vicente V; De Terán LC; Rivera J
    Blood Transfus; 2012 Oct; 10(4):480-9. PubMed ID: 22682335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
    Johnson L; Loh YS; Kwok M; Marks DC
    Transfus Med; 2013 Apr; 23(2):121-9. PubMed ID: 23480103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel system for storage of buffy-coat-derived platelet concentrates in a glucose-based platelet additive solution: parameters and metabolism during storage and comparison to plasma.
    Gyongyossy-Issa MI; Zhang JG; Culibrk B; Hunter F; Levin E; Scammell K; Weiss S; Holmes DL; Holme S
    Vox Sang; 2009 Aug; 97(2):102-9. PubMed ID: 19508670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.